Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (11)

Medical Condition

  • Show all (122)
  • Allergy, Asthma, & Immunology (1)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (6)
  • Bone & Muscle (1)
  • Cancer (72)
    • Brain Cancer (2)
    • Breast Cancer (1)
    • Head and Neck Cancer (1)
    • Kidney Cancer (1)
    • Leukemia (2)
    • (-) Lymphoma (6)
    • Pancreatic Cancer (1)
    • Prostate Cancer (1)
    • Sarcoma (1)
    • Skin Cancer (30)
      • Melanoma (19)
      • (-) Squamous Cell Carcinoma (5)
    • Solid Tumors (3)
  • COVID-19 (Coronavirus) (2)
  • Diabetes (1)
  • Hair and Skin Disorders (2)
  • Healthy Volunteers (11)
  • Heart Disease (3)
  • Infectious Disease (1)
  • Kidney Disease (1)
  • Lung Disease (5)
  • Neurological Disorders (4)
  • Obstetrics & Gynecology (2)
  • Pediatrics (4)
  • Psychiatric Disorders (1)
  • Rehabilitation (1)
  • Transplant (2)
  • Vascular Conditions (1)
Displaying 1 - 11 of 11

Study of Drug E7777 in Cutaneous T-Cell Lymphoma - Cancer of T-lymphocytes (type of white blood cells) that Involves the Skin

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of the Main study is to test the overall effects of E7777 on you and your illness. It is not known what effect E7777 will have on your illness or what the side effects will be. This study will look at the effect E7777 has on your body and your disease. It will also look at how your body absorbs, distributes, breaks down, and gets rid of the…
Read More

Phase 3 Trial to Determine the Efficacy of Topical Hypericin combined with Fluorescent Light Therapy on Cutaneous T-Cell Lymphoma

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by…
Read More

A study for patients with Cutaneous T-Cell Lymphoma/Mycosis Fungoides using topical lotion Naloxone in the treatment of itching

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
You are being asked to participate in a research study because you have Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and one of your symptoms is itching. This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF) which is a type of…
Read More

A study for patients with Cutaneous T Cell Lymphoma (CTCL) using study drug NM-IL-12

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a research study to test the effectiveness of NM-IL-12 an experimental drug, in combination with low dose Total Skin Electron Beam Therapy (TSEBT) for treatment of Cutaneous T Cell Lymphoma. The study will enroll 10 subjects age 18 years and older.Treatment will consist of 3 weeks of TSEBT, and up to 27 weeks of NM-IL…
Read More

Efficacy and Safety of Naloxone Lotion for Treatment of Itchiness in Patients with Mycosis Fungoides (MF) Form of Cutaneous T-cell Lymphoma

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 2 study to determine the efficacy and safety of Naloxone HCL Lotion 0.5% for the treatment of mycosis fungoides (MF) type of cutaneous T-cell lymphoma (CTCL). Selected subjects will have the study drug applied to determine its effect on reducing itchiness and any potential side effects. Naloxone has previously been approved for direct blood…
Read More

Study of Avelumab + Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual drug for treatment of your…
Read More

An observational study for patients diagnosed with mycosis fungoides cutaneous lymphoma and treated with Valchlor

Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to better understand the use of Valchlor in clinical practice. Other goals include describing the demographic and clinical characteristics of disease and health outcomes of patients treated with Valchlor. Participating in this study will not influence the usual care you receive from your doctor.
Read More

A study for patients with recurrent or metastatic squamous cell carcinoma of the Head and Neck using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly diagnosed. If newly diagnosed, the cancer must be metastatic,…
Read More

Study for patients with melanoma, non-small cell lung cancer (NSCLC) or squamous cell cancer of the head and neck (SCCHN) using drug B7-H3

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with melanoma, non-small cell lung cancer (NSCLC), or squamous cell cancer of the head and neck (SCCHN) that has a protein called B7-H3 on the tumor cells or blood vessels in thetumor. The purpose of this study is to test the safety, tolerability, and most effective dose ofMGA271 in combination with ipilimumab (also called Yervoy…
Read More

A study for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been made in the laboratory. MEDI4736 boosts the ability of your…
Read More

A study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck using study drug MEDI4736

Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science